Frontline therapy of multiple myeloma.
Blood
; 125(20): 3076-84, 2015 May 14.
Article
em En
| MEDLINE
| ID: mdl-25838345
ABSTRACT
In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Mieloma Múltiplo
Limite:
Humans
Idioma:
En
Revista:
Blood
Ano de publicação:
2015
Tipo de documento:
Article